Blood test may spare stomach cancer patients from unnecessary chemo

This study looks at whether a blood test that detects tiny bits of cancer DNA can help doctors decide if some patients can safely receive a milder treatment after surgery instead of standard chemotherapy. About 1,000 people with stage II to IVa stomach or gastro-esophageal cancer will be enrolled. After surgery and initial chemo, those with a negative blood test will either get standard chemo or a targeted drug alone, and researchers will compare how well each group does over time.